Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xuesaitong soft capsules plus aspirin in stable coronary artery disease with chronic superficial gastritis
ChiCTR-IPR-17012233Phase 4Not yet recruiting
- Sponsor
- Xiyuan Hospital
- Start
- Aug 2017
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of panax notoginseng and aspirin in coronary arteriosclerosis (2 arms), sponsored by Xiyuan Hospital. Primary endpoints: Platelet aggregation rate, Metabolites in arachidonic acid metabolic pathway and 1 more. Planned start Aug 2017; status: not yet recruiting.
02
Drugs
panax notoginsengaspirin
03
Conditions
coronary arteriosclerosis
Beyond the preview
Go deeper on ChiCTR-IPR-17012233.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPR-17012233.